Bayer Aktiengesellschaft (BAYZF)
OTCMKTS
· Delayed Price · Currency is USD
30.65
0.00 (0.00%)
Jun 26, 2025, 4:00 PM EDT
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 13.74B EUR in the quarter ending March 31, 2025, a decrease of -0.20%. This brings the company's revenue in the last twelve months to 46.58B, down -0.92% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
46.58B EUR
Revenue Growth
-0.92%
P/S Ratio
0.60
Revenue / Employee
507.04K EUR
Employees
91,864
Market Cap
30.20B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Elite Pharmaceuticals | 70.00M |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
American Oncology Network | 1.76B |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Bayer Aktiengesellschaft News
- 1 day ago - EY US & Bayer Win “Artificial Intelligence for Good” Award in 2025 AI Breakthrough Awards Program - GlobeNewsWire
- 3 days ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 8 days ago - Bayer’s stock is charting a 40% rebound after years of losses - Fortune
- 9 days ago - Bayer Files for Approval of gadoquatrane in the U.S. - Business Wire
- 10 days ago - Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients - GlobeNewsWire
- 10 days ago - Bayer Innovation Procurement Expands Use of Scientist.com's AI-Powered Platform for Global R&D Procurement Orchestration - Business Wire
- 16 days ago - Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies - Business Wire
- 21 days ago - Bayer raised to Buy at Goldman after hitting bottom of negative earnings revision cycle - Seeking Alpha